BR112020020118A2 - composto anti-cmklr1, molécula de ácido nucleico, vetor, célula hospedeira, produto de combinação, combinação de composto, método para selecionar um composto anti-cmklr1, e, composto agonista de cmklr1. - Google Patents

composto anti-cmklr1, molécula de ácido nucleico, vetor, célula hospedeira, produto de combinação, combinação de composto, método para selecionar um composto anti-cmklr1, e, composto agonista de cmklr1. Download PDF

Info

Publication number
BR112020020118A2
BR112020020118A2 BR112020020118-9A BR112020020118A BR112020020118A2 BR 112020020118 A2 BR112020020118 A2 BR 112020020118A2 BR 112020020118 A BR112020020118 A BR 112020020118A BR 112020020118 A2 BR112020020118 A2 BR 112020020118A2
Authority
BR
Brazil
Prior art keywords
seq
cmklr1
antibody
compound
amino acid
Prior art date
Application number
BR112020020118-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Vanessa Gauttier
Charlène Trilleaud
Marc Dubourdeau
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of BR112020020118A2 publication Critical patent/BR112020020118A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112020020118-9A 2018-04-03 2019-04-03 composto anti-cmklr1, molécula de ácido nucleico, vetor, célula hospedeira, produto de combinação, combinação de composto, método para selecionar um composto anti-cmklr1, e, composto agonista de cmklr1. BR112020020118A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305395 2018-04-03
EP18305395.8 2018-04-03
PCT/EP2019/058358 WO2019193029A1 (en) 2018-04-03 2019-04-03 Anti-chemokin like receptor 1 antibodies and their therapeutic applications

Publications (1)

Publication Number Publication Date
BR112020020118A2 true BR112020020118A2 (pt) 2021-02-23

Family

ID=62046804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020020118-9A BR112020020118A2 (pt) 2018-04-03 2019-04-03 composto anti-cmklr1, molécula de ácido nucleico, vetor, célula hospedeira, produto de combinação, combinação de composto, método para selecionar um composto anti-cmklr1, e, composto agonista de cmklr1.

Country Status (11)

Country Link
US (2) US20210147558A1 (enExample)
EP (2) EP4656247A2 (enExample)
JP (2) JP2021520210A (enExample)
KR (2) KR102802041B1 (enExample)
CN (2) CN112218894A (enExample)
AU (1) AU2019247068A1 (enExample)
BR (1) BR112020020118A2 (enExample)
CA (1) CA3102607A1 (enExample)
IL (2) IL277701A (enExample)
MA (1) MA52174A (enExample)
WO (1) WO2019193029A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730705B2 (en) * 2019-05-02 2023-08-22 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in inflammatory disease
EP3804754A1 (en) * 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
US20240084019A1 (en) * 2019-10-09 2024-03-14 Ose Immunotherapeutics Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications
EP4279142A4 (en) 2021-01-15 2024-12-04 Reel Tech Co., Ltd. PORTABLE EMERGENCY ESCAPE DEVICE
US11986512B2 (en) 2021-10-26 2024-05-21 Thetis Phamaceuticals LLC Compositions and methods for cancer therapy
WO2024028508A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
WO2024028509A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Treatment of an inflammation-associated disease in a patient expressing high chemerin level

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
US8038992B2 (en) * 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
US9195150B2 (en) * 2012-02-06 2015-11-24 Asml Netherlands B.V. Lithographic apparatus comprising a support for holding an object, and a support for use therein
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用

Also Published As

Publication number Publication date
US20210147558A1 (en) 2021-05-20
JP2024105648A (ja) 2024-08-06
IL277701A (en) 2020-11-30
CN120484119A (zh) 2025-08-15
WO2019193029A1 (en) 2019-10-10
AU2019247068A1 (en) 2020-10-22
IL321209A (en) 2025-07-01
MA52174A (fr) 2021-02-17
KR102802041B1 (ko) 2025-04-30
KR20210006359A (ko) 2021-01-18
KR20250065423A (ko) 2025-05-12
US20240400698A1 (en) 2024-12-05
EP3774899A1 (en) 2021-02-17
CN112218894A (zh) 2021-01-12
EP4656247A2 (en) 2025-12-03
JP2021520210A (ja) 2021-08-19
CA3102607A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
JP7092317B2 (ja) 抗ガレクチン－９抗体及びその使用
KR102714165B1 (ko) 인간 cd137에 결합하는 작동자 항체 및 이의 용도
US20210230266A1 (en) Il-11 antibodies
US20240400698A1 (en) Anti-chemokin like receptor 1 antibodies and their therapeutic applications
CN109369808B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
RU2662671C2 (ru) АНТИТЕЛО К АДРЕНОМЕДУЛЛИНУ (ADM) ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM HE-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ В ТЕРАПИИ
BR112020025502A2 (pt) Anticorpos il-11ra
US20250154244A1 (en) Anti-il-27 antibodies and uses thereof
CN113544151B (zh) 抗il-27抗体及其用途
JP7701915B2 (ja) 抗ケモカイン様受容体１ヒト化抗体及びその治療適用
JP2018513141A (ja) ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤
JP2022549854A (ja) 抗ｉｌ－２７抗体及びその使用
WO2024028508A2 (en) Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
EA049261B1 (ru) Гуманизированные антитела против хемокин-подобного рецептора 1 и их терапевтические применения
OA21239A (en) Anti-chemokin like receptor 1 humanized antibodies and their therapeutic applications.
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]